Related Experiment Videos
Malignant atrophic papulosis: treatment with aspirin and dipyridamole
Abstract:
On electron microscopy of the endothelial cells of a patient with cutaneous and CNS symptoms of malignant atrophic papulosis, paramyxovirus-like particles could be seen in the cytoplasm. These particles were interpreted as degenerative changes that were due to ischemia. Coagulation studies showed increased thrombocyte aggregation, and treatment with the platelet-suppressive drugs, aspirin and dipyridamole, was instituted. This treatment resulted in a normal thrombocyte aggregation after eight months and complete clinical remission, which still persisted four months after cessation of therapy.
Insights
Malignant atrophic papulosis treatment with aspirin and dipyridamole normalized thrombocyte aggregation. This led to complete clinical remission, demonstrating the efficacy of antiplatelet therapy for this rare vascular condition.
Area of Science:
- Vascular Biology
- Pathology
- Pharmacology
Background:
- Malignant atrophic papulosis (MAP) is a rare, severe vascular disease.
- Patients present with cutaneous and central nervous system (CNS) manifestations.
- Endothelial cell damage is a key pathological feature.
Observation:
- Electron microscopy revealed paramyxovirus-like particles in endothelial cell cytoplasm.
- These particles were attributed to ischemic damage.
- Coagulation studies indicated increased thrombocyte aggregation.
Findings:
- Treatment with aspirin and dipyridamole, both platelet-suppressive drugs, was initiated.
- Thrombocyte aggregation normalized after eight months of therapy.
- Complete clinical remission was achieved.
Implications:
- This suggests a potential role for platelet hyperaggregation in MAP pathogenesis.
- Antiplatelet therapy may be a viable treatment strategy for malignant atrophic papulosis.
- Further research into the underlying mechanisms of MAP is warranted.